Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A round brings $21mm to Antengene

Executive Summary

Qiming Capital led a $21mm Series A round for cancer and infectious disease-focused Antengene Corp. Huagai Capital, Tigermed and TF Capital also participated. Proceeds will support pipeline development, including work on ATG008, a TORC1/2 inhibitor for hepatocellular carcinoma in-licensed from Celgene earlier this year.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies